Durvalumab plus HAIC-FOLFOX followed by maintenance durvalumab for hepatocellular carcinoma with major portal invasion: phase 2 DurHope study

Junzhe Yi, Jiongliang Wang, Yimin Zhang, Xiongying Jiang, Song Chen, Jie Xu, Xintong Wu, Suixing Zhong, Qifeng Chen, Yue Hu, Yujia Song, Genjun Tan, Yunan Zhang, Jibin Li, Ming Zhao, Ning Lyu · 2026

Read Durvalumab plus HAIC-FOLFOX followed by maintenance durvalumab for hepatocellular carcinoma with major portal invasion: phase 2 DurHope study by Junzhe Yi, Jiongliang Wang, Yimin Zhang, Xiongying Jiang, Song Chen, Jie Xu, Xintong Wu, Suixing Zhong, Qifeng Chen, Yue Hu, Yujia Song, Genjun Tan, Yunan Zhang, Jibin Li, Ming Zhao, Ning Lyu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13439560.txt.

Description

Yi and co-authors ran this phase two trial in twenty twenty-six for advanced liver cancer. The patients had tumor growth invading the portal vein, a dire feature often left out of big trials. Treatment paired an immune drug, durvalumab, with chemotherapy pumped straight into the liver's artery. The chemo mix is known as FOLFOX.

Thirty patients received the pairing as their first treatment. The one-year survival rate reached about sixty-three percent, beating the preset goal. Median survival was just under fourteen months. Gene studies of tumors and blood suggested why some patients responded. Responders showed richer immune activity inside the tumor. Nonresponders carried resistance and immune escape signatures. Side effects were judged generally tolerable.

Catalog record

CREATORJunzhe Yi, Jiongliang Wang, Yimin Zhang, Xiongying Jiang, Song Chen, Jie Xu, Xintong Wu, Suixing Zhong, Qifeng Chen, Yue Hu, Yujia Song, Genjun Tan, Yunan Zhang, Jibin Li, Ming Zhao, Ning Lyu
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE80 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13439560

Browse the full library · About the Tower of Babel